Iowa Code §730.5 — The Iowa Drug and Alcohol Testing Act

Last verified: April 2026

Statutory Framework

Iowa Code §730.5, formally the Private Sector Drug-Free Workplaces statute, was originally enacted in 1987 and substantially amended in 1998 and again in 2025. Per the Iowa Supreme Court in Dix v. Casey’s General Stores, Inc. and Woods v. Charles Gabus Ford, Inc. (both 2021), §730.5 is “a comprehensive statute creating a detailed scheme employers must follow in utilizing workplace drug testing.”

Authorized Testing Categories

• Pre-employment testing — permitted with written policy.
• Reasonable suspicion testing — permitted with documented supervisor observation.
• Post-accident testing — permitted where injury occurred or property damage exceeded $1,000.
• Random testing of safety-sensitive employees — permitted under specific procedural rules.
• Federally mandated testing — for DOT, federal-contractor, and similarly regulated positions.

Specimen and Confirmation Rules

• Specimen types: urine, blood, oral fluid, and (for prospective employees only) hair.
• Written policy required. Employers must have a written drug-testing policy distributed to every employee subject to testing.
• Confirmation testing required. Initial positives must be confirmed by an HHS-certified / SAMHSA-certified laboratory using GC-MS or comparable methodology — Section 730.5 codifies the lab procedure standard.
• Notice to employees. Section 730.5(7) preserves the employee’s right to written notice of a positive result and the right to request a retest.
• Substance-abuse treatment opportunity. First-time positive test results require the employer to offer substance-abuse evaluation and treatment before termination — except for safety-sensitive positions and federally mandated testing. Section 730.5(15) preserves a reinstatement pathway after rehabilitation in some circumstances.
• Employer immunity. Section 730.5(11) grants compliance-based action immunity to employers who follow the statute.

Iowa Code §730.5 — the Iowa Drug and Alcohol Testing Act — permits broad pre-employment, random, and post-accident drug testing with a written employer policy. Iowa medical cannabidiol patients are not protected from termination based on a positive THC test (Iowa Code §124E.21).

Iowa Code §730.5; Iowa Code §124E.21

No Employment Protection for Medical Patients

Iowa Code §124E.21 explicitly does not extend any employment protection to medical cannabidiol cardholders. A registered patient who tests positive for THC under a §730.5-compliant employer policy can be lawfully terminated, even if the underlying use was off-duty and certified by an authorized Iowa healthcare practitioner.

This is in sharp contrast to the protections in:

• Connecticut (Conn. Gen. Stat. §21a-408p)
• New York (NY Labor Law §201-d, as amended by the MRTA)
• New Jersey (N.J.S.A. 24:6I-52)
• Pennsylvania (35 P.S. §10231.2103, as construed by Palmiter v. Commonwealth Health Systems)

Each of these states limits an employer’s ability to terminate or refuse to hire based solely on a positive THC test or medical-cannabis-cardholder status. Iowa offers no comparable protection.

The 2025 Amendments — HF 767

HF 767 (effective July 1, 2025) made §730.5 substantially more employer-friendly than the pre-2025 statute as construed by the Iowa Supreme Court in Dix and Woods:

• Burden of proof shifted to the employee/applicant, who must show by preponderance of evidence that a §730.5 violation directly caused damages.
• Notice requirements expanded — certified mail with return receipt is no longer the only acceptable notice method; in-person exchange or electronic notification is now permitted if the employee elects.
• “Safety-sensitive position” clarified as a position designated by the employer where an accident could cause loss of life, serious bodily injury, or significant property/environmental damage.

Federal Layer

Federal employers and federal contractors operate under the Drug-Free Workplace Act of 1988 (41 U.S.C. §81) and SAMHSA’s 5-panel federal drug test, which includes THC. Several federal regimes layer on top of Iowa law:

For Iowans with security-clearance positions (large at Collins Aerospace / RTX in Cedar Rapids and across the federal-contractor base), even a single positive on the federal panel can cost a clearance and the job that depends on it — medical-card status provides no defense.

Workers’ Compensation

Iowa Code §85.16 generally bars workers’ compensation when intoxication is the proximate cause of injury. Iowa Code Chapter 85 governs the framework. A registered Iowa medical cannabidiol patient who is injured at work and tests positive for THC may be denied compensation benefits even if cannabis use occurred off-duty — Iowa courts have applied the §85.16(2) bar where a metabolite is detected without requiring proof of impairment in some posture.

Combined with a positive test under a §730.5 policy, a workplace injury can result in termination and denial of benefits in a single incident.

Compare: The Workplace and the Highway

Iowa’s workplace and OWI rules are independently punitive on the same legal-elsewhere consumption. Under Iowa’s per se zero-tolerance OWI metabolite rule (Iowa Code §321J.2), THC-COOH metabolites detected in blood or urine constitute the offense without any showing of impairment. Metabolites can persist 30+ days after use.

An Iowan who consumes legally in Illinois on a Saturday faces:

• Workplace exposure: a random or post-accident test the following Wednesday at a Tyson, John Deere, or Collins Aerospace facility can produce a positive metabolite result and lawful termination under §730.5.
• Highway exposure: a traffic stop on the way home can produce an OWI charge under §321J.2 on the same metabolite, regardless of any actual impairment.

Both consequences flow from a single act of legal-elsewhere consumption. Iowa’s combination of (a) §730.5’s near-universal authorization of employer testing, (b) §124E.21’s explicit denial of workplace protection for medical patients, and (c) THC metabolite persistence of 30+ days in regular users means medical patients face an effective choice: use the medicine the state licenses them to use, or hold a job in any of the state’s largest industries. This is regularly cited in patient testimony to the Medical Cannabidiol Board.

Explore More